Evidence map›Paper›PMID 39692831›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025

Dynamic 18 F-FDG PET to detect differences among patients with progressive and relapsing multiple sclerosis: a pilot study.

Carlos Quintanilla-Bordás, Matías Fernández-Patón, Amadeo Ten, Cristina Ferrer-Pardo, Sara Carratala-Bosca, Jéssica Castillo-Villalba, Laura Cubas-Núñez, Raquel Gasqué-Rubio, Laura Verdini-Martínez, Francisco Pérez-Miralles and 2 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Carlos Quintanilla-BordásNeuroimmunology Unit, La Fe University and Polytechnic Hospital, Avda. Fernando Abril Martorell, 106, Valencia, 46026, Spain. carlosqb@gmail.com.ORCID http://orcid.org/0000-0002-4681-2456
Matías Fernández-PatónGrupo de Investigación Biomédica de Imagen, Health Research Institute Hospital La Fe, Valencia, Spain.
Amadeo TenGrupo de Investigación Biomédica de Imagen, Health Research Institute Hospital La Fe, Valencia, Spain.
Cristina Ferrer-PardoNeuroimmunology Unit, La Fe University and Polytechnic Hospital, Avda. Fernando Abril Martorell, 106, Valencia, 46026, Spain.
Sara Carratala-BoscaNeuroimmunology Unit, Health Research Institute Hospital La Fe, Valencia, Spain.
Jéssica Castillo-VillalbaNeuroimmunology Unit, Health Research Institute Hospital La Fe, Valencia, Spain.
Laura Cubas-NúñezNeuroimmunology Unit, Health Research Institute Hospital La Fe, Valencia, Spain.
Raquel Gasqué-RubioNeuroimmunology Unit, Health Research Institute Hospital La Fe, Valencia, Spain.
Laura Verdini-MartínezNeuroimmunology Unit, Health Research Institute Hospital La Fe, Valencia, Spain.
Francisco Pérez-MirallesNeuroimmunology Unit, La Fe University and Polytechnic Hospital, Avda. Fernando Abril Martorell, 106, Valencia, 46026, Spain.
Luís Martí-BonmatíMedical Imaging department, La Fe University and Polytechnic Hospital, Valencia, Spain.
Bonaventura CasanovaNeuroimmunology Unit, La Fe University and Polytechnic Hospital, Avda. Fernando Abril Martorell, 106, Valencia, 46026, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with multiple sclerosis (MS) may remain in a relapsing-remitting (RRMS) course despite long-standing disease, while others will develop secondary progression (SPMS). Chronic inflammation and changes in the blood-brain barrier resulting in perturbed glucose metabolism may account for these differences. PET-MRI with kinetic analysis of 2-deoxy-2(18 F)fluoro-d-glucose (18 F-FDG) provides insight into glucose metabolism and has proven useful in several chronic inflammatory diseases. However, to our knowledge, it has never been studied in MS.

objectiveTo explore potential differences in glucose distribution kinetics among individuals with long-standing SPMS and RRMS using dynamic 18-F-FDG PET-MRI.

methodsDynamic 18-F-FDG PET-MRI scans were obtained in 11 patients with long-standing MS: 4 with RRMS and 7 with SPMS. Kinetic analysis of PET data was performed using a three-compartment model equation that represents plasma, tissue and 18 F-FDG phosphorylation. Individual rate constants of 18-F-FDG across the compartments were calculated.

resultsPatients with SPMS exhibited a trend towards an increased net influx rate of glucose (p = 0.059) and an increased rate constant representing glucose phosphorylation. Together, the data suggest increased uptake of glucose and glycolysis in these patients.

conclusionDynamic 18 F-FDG PET-MRI is a feasible technique that may show information in vivo of glucose metabolism in MS. Although preliminary data suggest a potential radiological marker of progression in MS, further studies are required to confirm this hypothesis.

Indexed as

BrainFluorodeoxyglucose F18Multiple Sclerosis, Chronic ProgressiveMultiple Sclerosis, Relapsing-RemittingPositron-Emission TomographyAdultDisease ProgressionFemaleGlucoseHumansMagnetic Resonance ImagingMaleMiddle AgedPilot ProjectsRadiopharmaceuticalsFluorodeoxyglucose F18GlucoseRadiopharmaceuticals18 F-FDG kinetic analysisGlucose metabolismMultiple sclerosisSecondary progressive multiple sclerosis

Identifiers

PMID39692831

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.